Amlodipine Besylate Market Size was valued at USD 0.38 Billion in 2023. The Amlodipine Besylate industry is projected to grow from USD 0.40 Billion in 2024 to USD 0.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00% during the forecast period (2024 - 2032). The surge in the geriatric population in the region, the development of a wide range of therapeutics with amlodipine besylate, and the enhanced accessibility of pharmaceutical products are expected to be a significant market driver for the Amlodipine Besylate Market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for Amlodipine Besylate is being driven by the Increasing prevalence of hypertension and rising demand for managing high blood pressure. One of the main factors motivating the market is lifestyle changes, diet factors, and the aging population that is growing fast and contributing to an increase in market share. Statistically, the CDC indicated that 691,095 deaths in the US were attributed to hypertension in 2021 as the primary or contributing diagnosis. Being under one in four adults with hypertension with poor control of their condition seems to be the most common case (22.5%, 27.0 million). This makes the demand for amlodipine besylate even more solid. In 2050, elderly people are expected to fill approximately 80% of the population of low and middle-tier economies. By 2020, those aged 60 years and above had surpassed the number of children of less than 5 years. The world's population over sixty years old by 2050 will reach a level that is almost twice as high as the level in 2015, which was 12%.
The growing need to manage high blood pressure has stimulated the demand for amlodipine besylate as the primary medication. As the report by the Centers for Disease Control and Prevention indicates, the percentage of men who have high blood pressure (50%) is higher compared to the percentage of women (44%). Black non-Hispanic Americans have a relatively higher incidence of high blood pressure (56%) as compared to non-Hispanic whites (48%), non-Hispanic Asians (46%), and Hispanics (39%). As a result, it is anticipated that throughout the projection period, demand for the Amlodipine Besylate Market will increase due to the Increasing prevalence of hypertension and rising demand for managing high blood pressure. Thus, driving the Amlodipine Besylate Market revenue.
The Amlodipine Besylate Market segmentation, based on Type, includes 5 mg Tablets and 10 mg Tablets. The 5 mg Tablets segment dominated the market, accounting for 58% of market revenue. Amlodipine besylate has been observed to work effectively in combating the symptoms of hypertension and angina. Some patients can tolerate the 5 mg dose well, while others are more sensitive, preferring a stronger dosage. Usually, the 5 mg dose is the most effective, with a diminished risk of adverse effects, making it the favorite choice of prescribers everywhere. Proper adherence to the medication is critical for the effective management of chronic illnesses such as hypertension. The introduction of a 5 mg daily tablet in the market simplifies dosing regimens, which makes it easy for the patients to maintain compliance with treatment as opposed to multiple dosages or tablets with larger doses.
Figure 1: Amlodipine Besylate Market, by Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Amlodipine Besylate Market segmentation, based on Application, includes High Blood Pressure and Heart Diseases. The Heart disease segment dominated the market, accounting for 58% of market revenue. As shown by the Centers for Disease Control and Prevention, nearly half (47%, or 116 million) of U.S. adults suffer from hypertension, which is defined as having a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or is medicated for hypertension. In contrast to coronary artery disease, which is characterized by its rising prevalence, the chronic stable angina segment is projected to experience rapid growth throughout the forecast period.
By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Amlodipine Besylate market in North America can be attributed to several key factors. Amlodipine besylate is primarily applied for hypertension treatment and particular chest pain known as angina. Because of the increasing number of cardiovascular diseases in North America, more and more people need a kind of medication like amlodipine besylate to manage their condition. During these 33 seconds, another person dies of cardiovascular disease in the United States. 695,000 people in the United States died of heart disease in 2021, 1 in every 5 fatalities. Heart disease expenditures represented roughly $239.9 billion for the US during the 2018 - 2019 fiscal year.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Amlodipine Besylate Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Amlodipine Besylate Market accounts for the second-largest market share as there is increasing attention both from healthcare professionals and among the general public to the problem of prophylaxis and the risks that accompany it. In London, 30% of adults were hypertensive (high blood pressure), while 15% of this group had not been treated. Overall, the rates were more or less the same for both genders. According to age, the figure for total hypertension was 9% for adults aged 16 to 44 years, 54% for 45 to 64 years old, and 60% for adults aged 65 and over. This increase in awareness has led to the development of more proactive treatment approaches such as medication, for instance, amlodipine besylate. Further, the German Amlodipine Besylate Market held the largest market share, and the UK Amlodipine Besylate Market was the fastest-growing market in the European region.
The Asia-Pacific Amlodipine Besylate Market is expected to grow at the fastest CAGR from 2023 to 2032. Asia-Pacific's CVDs, including hypertension and coronary artery disease, are becoming more common because of sedentary living habits, unhealthy dietary patterns, and the aging population. The 2022 report called ‘Accidental Deaths & Suicides in India' mentioned the number of heart failure deaths ranging from 25,000 to 28,000 in the last four years. The civic health department, as per the report of 2022, stated that cardiovascular conditions were the reason behind every fourth death in Mumbai. The number of deaths was 94,500 in the city, inclusive of all the cases, with 25% of the entire deaths attributed to heart diseases and hypertension. Amlodipine besylate, a medication used to control hypertension and other cardiovascular diseases, has increased the demand for this medication. Moreover, China’s Amlodipine Besylate Market held the largest market share, and the Indian Amlodipine Besylate Market was the fastest-growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development to expand their product lines, which will help the Amlodipine Besylate market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Amlodipine Besylate industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Amlodipine Besylate industry to benefit clients and increase the market sector. In recent years, the Amlodipine Besylate industry has offered some of the most significant advantages to the healthcare sector. Major players in the Amlodipine Besylate Market, including Pfizer, Mylan, Reddy’s Laboratories, Apotex, Teva Pharmaceutical, Cipla, Hikma Pharmaceuticals, Strides Pharma, Upsher-Smith Laboratories, and InvaGen Pharmaceuticals, are attempting to increase market demand by investing in research and development operations.
Pfizer focuses on finding, developing, making, and selling biopharmaceuticals. The company has drugs for cardiovascular, metabolic, or pain problems, women’s health, cancer, inflammation, diseases, and rare elements of the immune system. It additionally offers sterilized injectable pharmaceuticals, biosimilars, and active pharmaceutical ingredients (API), as well as contract manufacturing services. Pfizer sells its products through wholesalers, drug stores, hospitals, private providers' offices, clinics, government agencies, and drug stores. Its main manufacturing plants are in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the United States. The company has already served the category in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer, the US, is headquartered in New York.
Cipla is a company that produces and markets branded medicines, generics, and active pharmaceutical ingredients (APIs). It provides the solution in the areas of cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, neurological, ophthalmic, cancer, malaria, respiratory and female urologic diseases, osteoporosis, and women's health. The company's medical supplies division expands into consumer healthcare and biosimilar firms. Cipla is engaged in the production of metered-dose inhalers, spacers, and other devices; it also engages in the research and development of new medicines and drug delivery systems. The Company operates in India, the US, Canada, South Africa, and other major regulated and emerging markets. Cipla is headquartered in Mumbai, which is in Maharashtra, India.
February 2024: Dr. Reddy’s Laboratories disclosed that it had attained a Voluntary Action Indicated (VAI) status from the United States Food and Drug Administration (USFDA) after an inspection of its research and development (R&D) centers for Integrated Product Development Organization (IPDO) in Bachupally, Hyderabad.
January 2024: Teva announced its plan to divest its active pharmaceutical ingredient (API) business, known as "TAPI." TAPI, a prominent player in the small molecule API sector, employs roughly 4,300 individuals globally.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.38 Billion |
| Market Size 2024 | USD 0.40 Billion |
| Market Size 2032 | USD 0.56 Billion |
| Compound Annual Growth Rate (CAGR) | 5.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled | Pfizer, Mylan, Reddy’s Laboratories, Apotex, Teva Pharmaceutical, Cipla, Hikma Pharmaceuticals, Strides Pharma, Upsher-Smith Laboratories, and InvaGen Pharmaceuticals |
| Key Market Opportunities | · Huge investments in the pharmaceutical business |
| Key Market Dynamics | · High prevalence of hypertension and cardiovascular diseases |
Frequently Asked Questions (FAQ) :
The Amlodipine Besylate Market size was valued at USD 0.38 Billion in 2023.
The Amlodipine Besylate Market is projected to grow at a CAGR of 5.00% during the forecast period, 2024-2032.
North America had the largest share of the global market.
The key players in the market are Pfizer, Mylan, Reddy’s Laboratories, Apotex, Teva Pharmaceutical, Cipla, Hikma Pharmaceuticals, Strides Pharma, Upsher-Smith Laboratories, and InvaGen Pharmaceuticals.
The 5 mg Tablets segment dominated the market in 2023.
The heart disease segment had the largest share of the global market.
Research Analyst Level I In her 3 years of experience in the market research field, she has handled critical cross-domain projects. she has an in-depth knowledge of market estimation & analysis, problem-solving, primary as well as secondary research, and team management.she holds an engineering degree and is an mba professional from a well-known university, capable of evaluating the market and competitive conditions. an exceptional strategist with excellent communication skills and a passion for delivering cutting-edge & practical insights for the market. proficient in multi-tasking, and can successfully deal with competing demands, while maintaining complete confidentiality. generated business through active client and project development, networking, and high-quality responses. her knowledge and skills have helped in making solid business decisions, securing funding from investors, and avoiding business failures.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
